GlassScriptPhysician profile
Surinder Kohal
NPI 1699766915
$2,891.25
in general payments reported to CMS, 2019-2025
23 companies · $966 in 2025
The $966 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $27.05 · 2022: $58.96 · 2023: $701 · 2024: $909 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.96 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $668.97 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $322.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $294.55 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $257.52 | 2019-2024 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $254.95 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.32 | 2023-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $166.97 | 2023-2025 | |
| Pfizer INC. | $142.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $131.59 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $113.75 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.42 | 2023-2025 | Jardiance |
| Sanofi Pasteur INC. | $32.92 | 2019 | |
| Lundbeck LLC | $29.50 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $26.82 | 2025 | |
| Vertiflex, INC. | $26.52 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.45 | 2025 | Dexcom G6 Transmitter |
| Agios Pharmaceuticals, INC. | $24.54 | 2025 | Pyrukynd |
| Sumitomo Pharma America, INC. | $22.43 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $21.37 | 2025 | Heplisav-B |
| Globus Medical, INC. | $21.17 | 2025 | Senza |
| Abbvie INC. | $16.51 | 2025 | |
| Medtronic USA, INC. | $15.50 | 2019 | |
| Astellas Pharma US INC | $15.16 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surinder Kohal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.